ANTITHYMOCYTE IMMUNOGLOBULINS INJECTION bulk supplier for pharma manufacturers

Antithymocyte Immunoglobulins Injection 25mg, 100 mg, 500 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 25mg, 100 mg, 500 mg

Reference Brands: Thymoglobulin (USA/EU/LATAM), Fresenius ATG (EU)

This injection is a purified and sterile form of gamma globulin. It is isolated from the hyperimmune plasma of horses immunized with human white blood cell components. It is used after kidney transplantation along with other therapies to treat as well as delay organ rejection.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

After solid organ transplantation, the body generates an aggressive immune response because it recognizes the transplanted organ's antigens as a foreign antigen. Thus, treatment with immunosuppressive agents is necessary after an organ transplant to prevent organ rejection.

Antithymocyte Globulin (ATG) is a purified antibody preparation derived from rabbits or horses that have been hyperimmunized with human thymocytes. It is a potent immunosuppressive agent used primarily to prevent and treat acute cellular rejection following solid organ transplantation, including kidney, heart, and liver transplants. ATG is also employed in the management of acute aplastic anemia and other severe immune-mediated hematologic disorders. By targeting T-lymphocytes, ATG reduces the immune response, helping to prevent graft-versus-host disease and improve transplant outcomes.

Although ATG is highly effective, it can cause transient elevations in serum enzymes shortly after infusion, and it carries a risk of reactivating hepatitis B in susceptible patients. Common adverse effects include fever, chills, hypotension, and infusion-related reactions, which typically require careful monitoring during administration. Its mechanism, dosing, and safety profile necessitate skilled oversight by healthcare professionals. Overall, ATG remains an essential therapy in transplantation and certain hematologic conditions due to its ability to modulate the immune system effectively while reducing the risk of organ rejection and immune-mediated complications.

Antithymocyte Immunoglobulins Injection — third party manufacturing & bulk supply

Antithymocyte Immunoglobulins Injection 25mg, 100 mg, 500 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Antithymocyte Immunoglobulins Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Antithymocyte Immunoglobulins Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Antithymocyte Immunoglobulins Injection →

Back to Listing

Frequently Asked Questions

Antithymocyte Immunoglobulin (ATG) is used primarily to prevent and treat acute organ transplant rejection, especially in kidney, heart, or liver transplantation. It is also used in the management of aplastic anemia and other severe immune-mediated hematologic disorders. ATG works by depleting T-lymphocytes, suppressing the immune response, and reducing the risk of graft-versus-host disease (GVHD) in transplant patients.

ATG is prepared from the serum of rabbits or horses that have been immunized with human thymocytes, resulting in antibodies that target human T-cells. These antibodies are purified to produce the immunoglobulin formulation.

Common trade names include Thymoglobulin, ATGAM, Grafalon, Fresenius ATG, and Thymoglobuline.

ATG products are manufactured by several pharmaceutical companies including Sanofi, Neovii Biotech, and Fresenius Kabi.

The generic name is Antithymocyte Immunoglobulin.

Common brand names include Thymoglobulin, ATGAM, Grafalon, Fresenius ATG, and Thymoglobuline.

ATG products are manufactured in several countries including the United States, Germany, Switzerland, and other regions by different pharmaceutical companies specializing in immunoglobulin therapies.